BELLUS Health Stock Shines After Refractory Chronic Cough Trial Data

by Vandana Singh, Benzinga Editor

September 13, 2021 8:36 AM | 1 min read |

BELLUS Health Inc BLU has announced a positive interim analysis from Phase 2b SOOTHE trial of BLU-5937 for refractory chronic cough (RCC).
BLU-5937, the Company's lead program, is a highly selective P2X3 antagonist.
An independent statistical team reported that the predefined stringent probability threshold for clinical efficacy was met for at least one dose of BLU-5937 for a clinically meaningful reduction in placebo-adjusted 24-hour cough frequency.
Limited taste-related adverse events were observed, consistent with previous BLU-5937 trials, and no serious adverse events were reported.
BELLUS anticipates announcing topline data in Q4 of 2021.
Price Action: BLU shares are up 36% at $5.33 during the premarket session on the last check Monday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.